ImmunityBio's Options Traders Bet Big on Growth Despite Legal Headwinds

A surge in bullish options activity is painting a starkly optimistic picture for ImmunityBio, even as the biotech firm navigates significant regulatory and legal challenges. The stock's put/call ratio has dropped to 0.36, indicating nearly three bullish bets for every bearish one, as call volume spikes well above average levels. This sentiment shift follows the company's explosive first-quarter revenue report and comes ahead of a critical legal deadline for shareholders.

ImmunityBio reported preliminary net product revenue of approximately $44.2 million for Q1 2026, a staggering 168% increase from the same period last year. Sequentially, sales grew 15% from the fourth quarter of 2025, suggesting sustained commercial momentum for its bladder cancer immunotherapy, ANKTIVA. The stock responded positively to the news, climbing 12% on the report and gaining in six of the last ten trading sessions to reach $7.70, a 6.2% recent increase.

This commercial strength is underpinned by a solid financial position. The company ended March with roughly $380.9 million in cash and liquid assets, bolstered by a $75 million non-dilutive financing round closed late in the quarter. For the full year 2025, total revenue reached $113.3 million, a massive jump from $14.8 million in 2024, while net losses contracted by over 15%.

However, a major overhang persists from a regulatory misstep. On March 24, 2026, Bloomberg reported that the U.S. Food and Drug Administration had sent ImmunityBio a warning letter concerning misleading promotional claims. The letter cited statements made by the company's Executive Chairman in a podcast, where he suggested ANKTIVA could "cure and even prevent all cancers." The news triggered a single-day stock collapse of more than 21%, wiping out nearly $2 billion in market capitalization.

Should investors sell immediately? Or is it worth buying ImmunityBio?

In response, ImmunityBio removed the contentious podcast from its website, requested its deletion from third-party platforms, and confirmed a referenced TV commercial never aired. The company submitted a comprehensive formal response to the FDA's Office of Prescription Drug Promotion on April 6, 2026.

The incident sparked a securities fraud class action lawsuit covering investors who purchased stock between January 19 and March 24, 2026. A key procedural deadline is fast approaching: investors have until May 26, 2026, to apply for lead plaintiff status in the ongoing litigation.

Operationally, the company continues to advance. ANKTIVA is now approved in five regulatory jurisdictions covering approximately 33 countries. In Europe, the European Commission granted conditional marketing authorization for non-muscle invasive bladder cancer, with a rollout supported by partner Accord Healthcare and a dedicated sales force across 30 nations.

ImmunityBio at a turning point? This analysis reveals what investors need to know now.

Clinically, the pivotal QUILT-2.005 study for BCG-naive patients is fully enrolled. An independent data monitoring committee has confirmed the trial has sufficient statistical power, and a supplemental Biologics License Application submission to the FDA remains on track for 2026. The company's founder has also presented new clinical data for ANKTIVA in breast cancer, hinting at a broader platform strategy.

The contrasting narratives are clear: record-breaking commercial execution and pipeline progress on one side, versus substantial regulatory and legal risk on the other. How these forces balance out, particularly as the May legal deadline passes and the company prepares its key regulatory filing later this year, will likely dictate the stock's trajectory for the remainder of 2026.

Ad

ImmunityBio Stock: New Analysis - 21 April

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated ImmunityBio analysis...

en | US45256X1037 | IMMUNITYBIOS | boerse | 69231645 |